Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Universal Donor Natural Killer Cells in Combination with Aldesleukin and Vactosertib for the Treatment of Patients with Locally Advanced or Metastatic Colorectal, Gastric and Esophageal Cancers and Relapsed or Refractory Hematologic Cancers

Trial Status: active

This phase Ib trial tests the safety of natural killer (NK) cells with aldesleukin and vactosertib in treating patients with colorectal, gastric and esophageal cancers that has spread to nearby tissue or lymph nodes (locally advanced) or has spread to other places in the body (metastatic) or hematologic cancers that has come back (relapsed) or does not respond to treatment (refractory). One of the ways that cancer grows and spreads is by avoiding the immune system. NK cells are immune cells that kill cancer cells, but are often malfunctioning in people with colorectal cancer and blood cancers. Natural killer cells are a type of white blood that are part of the body's defense system that kill cancer cells. NK cells in cancer patients are not able to kill cancer cells. Universal donor NK cells are cells from a healthy person. Chemotherapy before a donor NK cell transplant prepares the body by white blood cells so that they do not reject the NK cells. Aldesleukin activates donor NK cells. Vactosertib may activate donor NK cells. Giving NK cells from a healthy donor with aldesleukin and vactosertib may help to control cancer and tumor cells.